NIH funds HIV microbicide study
This article was originally published in The Tan Sheet
Executive Summary
A National Institutes of Health-funded study on the safety of its vaginal microbicide gel VivaGel (SPL7013) has begun, Starpharma Holdings announces July 10. The gel, intended to be used for the prevention of HIV and genital herpes, is being tested in 40 sexually active, HIV-negative women aged 18 to 24 for its safety, acceptability and ease of use at the University of South Florida in Tampa and the University of Puerto Rico in San Juan. Starpharma says it expects the product will ultimately be OTC, but in some markets it may be initially offered by prescription. In 2005 NIH funded a study on Indevus Pharmaceuticals' microbicide PRO 2000 (1"The Tan Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
NIH microbicide trial
The National Institute of Allergy & Infectious Diseases will fund a trial evaluating the safety and efficacy of Indevus Pharmaceuticals' topical microbicide PRO 2000, the firm announces Feb. 11. The study is expected to include 3,220 women recruited from five African countries - Malawi, South Africa, Tanzania, Zambia and Zimbabwe - and has an expected duration of 30 months. Participants will be placed into four equally sized groups and receive either PRO 2000, a second microbicide, a placebo gel or no gel. All participants also will receive condoms and prevention counseling during visits to the participating clinics. Study authors will "evaluate the effectiveness of the candidate microbicides in preventing HIV and other sexually transmitted infections, including gonorrhea, herpes and chlamydia," Indevus says, noting PRO 2000 is still in development. Panelists at an FDA Antiviral Drugs Advisory Committee meeting recommended a three-armed trial to study microbicides' net benefit (1"The Tan Sheet" Aug. 25, 2003, p. 7)...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.